Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
VREX's Cash-to-Debt is ranked higher than
75% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. VREX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
VREX' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.86
VREX's Equity-to-Asset is ranked higher than
86% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. VREX: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
VREX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.83  Med: 0.85 Max: 0.86
Current: 0.86
0.83
0.86
Interest Coverage 49.47
VREX's Interest Coverage is ranked lower than
55% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. VREX: 49.47 )
Ranked among companies with meaningful Interest Coverage only.
VREX' s Interest Coverage Range Over the Past 10 Years
Min: 49.47  Med: 150.91 Max: 422
Current: 49.47
49.47
422
Altman Z-Score: 9.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 15.58
VREX's Operating Margin % is ranked higher than
83% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. VREX: 15.58 )
Ranked among companies with meaningful Operating Margin % only.
VREX' s Operating Margin % Range Over the Past 10 Years
Min: 15.58  Med: 22.68 Max: 25.69
Current: 15.58
15.58
25.69
Net Margin % 9.91
VREX's Net Margin % is ranked higher than
81% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. VREX: 9.91 )
Ranked among companies with meaningful Net Margin % only.
VREX' s Net Margin % Range Over the Past 10 Years
Min: 9.91  Med: 14.36 Max: 16.36
Current: 9.91
9.91
16.36
ROE % 9.70
VREX's ROE % is ranked higher than
65% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. VREX: 9.70 )
Ranked among companies with meaningful ROE % only.
VREX' s ROE % Range Over the Past 10 Years
Min: 9.7  Med: 18.96 Max: 61.29
Current: 9.7
9.7
61.29
ROA % 9.60
VREX's ROA % is ranked higher than
84% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. VREX: 9.60 )
Ranked among companies with meaningful ROA % only.
VREX' s ROA % Range Over the Past 10 Years
Min: 9.6  Med: 15.74 Max: 50.84
Current: 9.6
9.6
50.84
ROC (Joel Greenblatt) % 26.50
VREX's ROC (Joel Greenblatt) % is ranked higher than
70% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. VREX: 26.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VREX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 26.5  Med: 44.61 Max: 132.5
Current: 26.5
26.5
132.5
GuruFocus has detected 2 Warning Signs with Varex Imaging Corp $VREX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VREX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

VREX Guru Trades in

VREX Guru Trades in

VREX Guru Trades in

Q4 2016

VREX Guru Trades in Q4 2016

John Hussman 4,000 sh (unchged)
First Eagle Investment 1,727,224 sh (unchged)
Columbia Wanger 133,560 sh (unchged)
Charles Brandes 65,414 sh (unchged)
Richard Pzena 1,144 sh (unchged)
John Rogers 8,040 sh (unchged)
Paul Tudor Jones 7,466 sh (unchged)
Joel Greenblatt 135,047 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with VREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334517    SIC: 3844
Compare:NAS:MYGN, NAS:FMI, NAS:MEDP, NAS:GHDX, NAS:AXDX, NAS:ABAX, NAS:KANG, NAS:BEAT, NAS:ALOG, NAS:QDEL, NAS:HSKA, NAS:NRCIA, NAS:VIVO, NAS:NEO, NYSE:ARA, NAS:LNTH, NAS:NTRA, NYSE:NVTA, NYSE:ENZ, NAS:NVDQ » details
Headquarter Location:USA
Varex Imaging Corp is engaged in designing and manufacturing of X-ray tubes, flat panel detectors, imaging software and inspection accelerators.

Ratios

vs
industry
vs
history
PE Ratio 21.56
VREX's PE Ratio is ranked higher than
70% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. VREX: 21.56 )
Ranked among companies with meaningful PE Ratio only.
VREX' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.4
Current: 21.56
0
23.4
PE Ratio without NRI 21.56
VREX's PE Ratio without NRI is ranked higher than
69% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. VREX: 21.56 )
Ranked among companies with meaningful PE Ratio without NRI only.
VREX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.4
Current: 21.56
0
23.4
PB Ratio 2.26
VREX's PB Ratio is ranked higher than
73% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. VREX: 2.26 )
Ranked among companies with meaningful PB Ratio only.
VREX' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.5
Current: 2.26
0
2.5
PS Ratio 3.85
VREX's PS Ratio is ranked lower than
52% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. VREX: 3.85 )
Ranked among companies with meaningful PS Ratio only.
VREX' s PS Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.24
Current: 3.85
0
4.24
Price-to-Free-Cash-Flow 43.40
VREX's Price-to-Free-Cash-Flow is ranked lower than
73% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. VREX: 43.40 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VREX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 47.15
Current: 43.4
0
47.15
Price-to-Operating-Cash-Flow 32.61
VREX's Price-to-Operating-Cash-Flow is ranked lower than
77% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. VREX: 32.61 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VREX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 35.45
Current: 32.61
0
35.45
EV-to-EBIT 15.76
VREX's EV-to-EBIT is ranked higher than
70% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. VREX: 15.76 )
Ranked among companies with meaningful EV-to-EBIT only.
VREX' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0 Max: 17.96
Current: 15.76
0
17.96
EV-to-EBITDA 13.46
VREX's EV-to-EBITDA is ranked higher than
66% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. VREX: 13.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
VREX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0 Max: 15.41
Current: 13.46
0
15.41
Current Ratio 4.94
VREX's Current Ratio is ranked higher than
76% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. VREX: 4.94 )
Ranked among companies with meaningful Current Ratio only.
VREX' s Current Ratio Range Over the Past 10 Years
Min: 4.02  Med: 4.63 Max: 4.94
Current: 4.94
4.02
4.94
Quick Ratio 2.25
VREX's Quick Ratio is ranked higher than
53% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. VREX: 2.25 )
Ranked among companies with meaningful Quick Ratio only.
VREX' s Quick Ratio Range Over the Past 10 Years
Min: 1.8  Med: 2.03 Max: 2.25
Current: 2.25
1.8
2.25
Days Inventory 193.73
VREX's Days Inventory is ranked lower than
87% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. VREX: 193.73 )
Ranked among companies with meaningful Days Inventory only.
VREX' s Days Inventory Range Over the Past 10 Years
Min: 62.66  Med: 150.37 Max: 193.73
Current: 193.73
62.66
193.73
Days Sales Outstanding 85.45
VREX's Days Sales Outstanding is ranked lower than
67% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. VREX: 85.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
VREX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68  Med: 68.56 Max: 85.45
Current: 85.45
68
85.45
Days Payable 49.76
VREX's Days Payable is ranked lower than
55% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. VREX: 49.76 )
Ranked among companies with meaningful Days Payable only.
VREX' s Days Payable Range Over the Past 10 Years
Min: 37.52  Med: 41.14 Max: 49.76
Current: 49.76
37.52
49.76

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 4.42
VREX's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. VREX: 4.42 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VREX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.68
Current: 4.42
0
4.68
Price-to-Tangible-Book 2.62
VREX's Price-to-Tangible-Book is ranked higher than
76% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. VREX: 2.62 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VREX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.77
Current: 2.62
0
2.77
Price-to-Graham-Number 1.58
VREX's Price-to-Graham-Number is ranked lower than
99.99% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. VREX: 1.58 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VREX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.68
Current: 1.58
0
1.68
Earnings Yield (Greenblatt) % 6.32
VREX's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. VREX: 6.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VREX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -198.44  Med: 0 Max: 6.81
Current: 6.32
-198.44
6.81

More Statistics

Revenue (TTM) (Mil) $476.3
EPS (TTM) $ 1.56
Short Percentage of Float9.96%
52-Week Range $25.00 - 36.58
Shares Outstanding (Mil)37.39

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)